CVR number 32836747
Industry 477800

LEMVIG BIO BRÆNDSEL ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  10.9% 11.4% 10.5% 9.5% 9.5%  
Credit score (0-100)  23 21 22 25 25  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  162 118 179 303 678  
EBITDA  162 118 168 180 290  
EBIT  148 104 154 166 269  
Pre-tax profit (PTP)  134.9 81.7 138.1 142.5 245.1  
Net earnings  90.0 63.5 107.7 115.2 191.2  
Pre-tax profit without non-rec. items  135 81.7 138 142 245  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  792 778 764 749 777  
Shareholders equity total  225 288 396 511 643  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,300 1,382 1,536 1,754 2,072  
Net Debt  -179 -21.0 -290 -177 -372  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  162 118 179 303 678  
Gross profit growth  -1.3% -27.4% 52.3% 68.9% 123.7%  
Employees  0 0 0 0 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,300 1,382 1,536 1,754 2,072  
Balance sheet change%  3.9% 6.3% 11.1% 14.2% 18.1%  
Added value  162.2 117.8 168.1 179.8 290.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -28 -28 -28 -28 7  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  3.0 4.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  91.3% 88.0% 85.9% 54.7% 39.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  12.3% 7.8% 11.1% 10.1% 14.2%  
ROI %  82.6% 37.4% 44.1% 34.4% 44.6%  
ROE %  50.1% 24.8% 31.5% 25.4% 33.1%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  17.3% 20.9% 25.8% 29.1% 31.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -110.1% -17.8% -172.7% -98.6% -128.2%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.3 0.3 0.5 0.7 0.8  
Current Ratio  0.5 0.6 0.7 0.8 0.9  
Cash and cash equivalent  178.7 21.0 290.3 177.3 371.8  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -547.2 -465.5 -339.9 -209.6 -176.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 290  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 290  
EBIT / employee  0 0 0 0 269  
Net earnings / employee  0 0 0 0 191